HEADLINES: • Diagnostyka: take a test (BUY - initiation of coverage) • EME Macro/Strategy: Ukraine – a macro primer • EME Macro/Strategy: Ukraine’s peace deal – WOOD’s equity playbook • EMEA airlines: some notes on the potential Ukraine reopening • Aegean Airlines: 4Q24 – material beat vs. our estimates, on higher revenue and lower employee costs POSITIVE • Dom Development: 4Q24 – strongest year on record POSITIVE • Vercom: 4Q24 results review – 29% yoy EBITDA growth, in line with the consensus ...
We initiate coverage of Diagnostyka with a BUY rating and a 12M price target (PT) of PLN 159/share. Diagnostyka is the leader of the Polish medical diagnostics market, with a 22% share in the total addressable medical laboratory testing market and 49% in the private segment. Operating in the hub-and-spoke model, the company combines economies of scale with superior proximity and attractive prices. By 2028E, Diagnostyka’s management expects to double its sales, outperforming Bain and Co.’s market...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.